NG25

• Description :

  NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H413

• Target :

  MAP3K; MAP4K

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/NG25.html

• Purity :

  98.30

• Solubility :

  DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(NC1=CC(C(F)(F)F)=C(CN(CC2)CCN2CC)C=C1)C3=CC(OC4=C5C(NC=C5)=NC=C4)=C(C)C=C3

• Molecular Formula :

  C29H30F3N5O2

• Molecular Weight :

  537.58

• Precautions :

  H301, H413

• References & Citations :

  [1]Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) . J Med Chem. 2015 Jan 8;58 (1) :183-96.|[2]Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287 (23) :19216-28.|[3]Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  MAP3K7/TAK1; MAP4K2/GCK

• CAS Number :

  [1315355-93-1]